Palvella Therapeutics, Inc. filed a current report on Form 8-K on October 28, 2026, disclosing that the U.S. Food and Drug Administration accepted for filing and granted Priority Review to the company's New Drug Application for QTORIN 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations.

Key Highlights

  • Priority Review granted: The FDA accepted for filing and granted Priority Review to Palvella's New Drug Application for QTORIN 3.9% rapamycin anhydrous gel.
  • Indication: The NDA covers treatment of microcystic lymphatic malformations.
  • PDUFA date assigned: The FDA assigned a Prescription Drug User Fee Act target action date of February 28, 2027.
  • Announcement date: The company issued a press release on October 28, 2026, describing the regulatory development.
  • Signed by CFO: The filing was signed by Matthew Korenberg, Chief Financial Officer of Palvella Therapeutics, Inc.

Palvella Therapeutics Receives FDA Priority Review for QTORIN NDA

According to the filing, Palvella Therapeutics, Inc. (NASDAQ:PVLA) announced on October 28, 2026, that the FDA has accepted for filing and granted Priority Review to its New Drug Application for QTORIN 3.9% rapamycin anhydrous gel. The NDA targets the treatment of microcystic lymphatic malformations, a rare condition. The company disclosed this development through a press release, a copy of which was filed as Exhibit 99.1 to the current report.

The filing states that the FDA has assigned a Prescription Drug User Fee Act, or PDUFA, target action date of February 28, 2027. Priority Review designation, as referenced in the filing, indicates that the FDA has set a shorter review timeline than a standard review. The company is incorporated in Nevada and is headquartered at 353 W. Lancaster Ave, Suite 200, Wayne, Pennsylvania 19087.

The current report was signed by Matthew Korenberg in his capacity as Chief Financial Officer. No financial statements were included in this filing. The company did not indicate in the filing that it is an emerging growth company.

What Was Disclosed

Palvella Therapeutics disclosed via an October 28, 2026, Form 8-K that the FDA accepted its NDA for QTORIN 3.9% rapamycin anhydrous gel and granted Priority Review, with a PDUFA target action date of February 28, 2027.